inclusion criteria: * subjects aged ≥18. * body temperature \< 37.3 ° c confirmed by clinical examination before enrollment . * cd4+ count is less than 500/ul and more than 50/ul . * female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. * able and willing to complete the entire study plan during the study follow-up period. * have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. exclusion criteria for the first dose: * being allergic to any component of vaccines (including excipients) . * subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). * having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome. * pregnant and lactating women. * the subjects are suffering from an acute illness; or thrombocytopenia patients with platelet count \< 20×10\^9/l within three days before inoculation, that is, patients at high risk of spontaneous bleeding. * acute hiv infection and opportunistic infection. * subjects with co-opportunistic infections who did not receive antiviral therapy. * subjects with cd4+ count less than 50/ul who have not received antiviral therapy. * hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. * other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies. exclusion criteria for the second dose: * subjects who had vaccine-related adverse reactions after the first dose. * having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction. * having any adverse nervous system reaction after the first dose. * during the acute onset of a chronic disease, or the recovery of acute complications less than two weeks. * subjects with severe immunodeficiency (cd4+ count less than 50/ul). * acute hiv infection and opportunistic infection. * subjects with co-opportunistic infections who did not receive antiviral therapy. * hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * other reasons for exclusion considered by the investigator.

inclusion criteria: * subjects aged ≥18. * body temperature \< 37.3 ° c confirmed by clinical examination before enrollment . * cd4+ count is less than 500/ul and more than 50/ul . * female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. * able and willing to complete the entire study plan during the study follow-up period. * have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. exclusion criteria for the first dose: * being allergic to any component of vaccines (including excipients) . * subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). * having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome. * pregnant and lactating women. * the subjects are suffering from an acute illness; or thrombocytopenia patients with platelet count \< 20×10\^9/l within three days before inoculation, that is, patients at high risk of spontaneous bleeding. * acute hiv infection and opportunistic infection. * subjects with co-opportunistic infections who did not receive antiviral therapy. * subjects with cd4+ count less than 50/ul who have not received antiviral therapy. * hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. * other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies. exclusion criteria for the second dose: * subjects who had vaccine-related adverse reactions after the first dose. * having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction. * having any adverse nervous system reaction after the first dose. * during the acute onset of a chronic disease, or the recovery of acute complications less than two weeks. * subjects with severe immunodeficiency (cd4+ count less than 50/ul). * acute hiv infection and opportunistic infection. * subjects with co-opportunistic infections who did not receive antiviral therapy. * hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * other reasons for exclusion considered by the investigator.

inclusion criteria: - subjects aged ≥18. - body temperature < 37.3 ° c confirmed by clinical examination before enrollment . - cd4+ count is less than 500/ul and more than 50/ul . - female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. - able and willing to complete the entire study plan during the study follow-up period. - have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. exclusion criteria for the first dose: - being allergic to any component of vaccines (including excipients) . - subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). - having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome. - pregnant and lactating women. - the subjects are suffering from an acute illness; or thrombocytopenia patients with platelet count < 20×10^9/l within three days before inoculation, that is, patients at high risk of spontaneous bleeding. - acute hiv infection and opportunistic infection. - subjects with co-opportunistic infections who did not receive antiviral therapy. - subjects with cd4+ count less than 50/ul who have not received antiviral therapy. - hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). - patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. - other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies. exclusion criteria for the second dose: - subjects who had vaccine-related adverse reactions after the first dose. - having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction. - having any adverse nervous system reaction after the first dose. - during the acute onset of a chronic disease, or the recovery of acute complications less than two weeks. - subjects with severe immunodeficiency (cd4+ count less than 50/ul). - acute hiv infection and opportunistic infection. - subjects with co-opportunistic infections who did not receive antiviral therapy. - hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). - other reasons for exclusion considered by the investigator.

inclusion criteria: - subjects aged ≥18. - body temperature < 37.3 ° c confirmed by clinical examination before enrollment . - cd4+ count is less than 500/ul and more than 50/ul . - female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. - able and willing to complete the entire study plan during the study follow-up period. - have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. exclusion criteria for the first dose: - being allergic to any component of vaccines (including excipients) . - subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). - having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome. - pregnant and lactating women. - the subjects are suffering from an acute illness; or thrombocytopenia patients with platelet count < 20×10^9/l within three days before inoculation, that is, patients at high risk of spontaneous bleeding. - acute hiv infection and opportunistic infection. - subjects with co-opportunistic infections who did not receive antiviral therapy. - subjects with cd4+ count less than 50/ul who have not received antiviral therapy. - hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). - patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. - other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies. exclusion criteria for the second dose: - subjects who had vaccine-related adverse reactions after the first dose. - having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction. - having any adverse nervous system reaction after the first dose. - during the acute onset of a chronic disease, or the recovery of acute complications less than two weeks. - subjects with severe immunodeficiency (cd4+ count less than 50/ul). - acute hiv infection and opportunistic infection. - subjects with co-opportunistic infections who did not receive antiviral therapy. - hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). - other reasons for exclusion considered by the investigator.